An irreversible oral pan-ERBB inhibitor targeting HER1, HER2, and HER4, pyrotinib, has been demonstrated to be another promising agent for the treatment of HER2+ metastatic BC; however, there are no data on cohort stratification of the type of metastasis available [9]. Here, ERBB2 is linked to breast cancer.